It's difficult to push against all the negativity here, but I'll give it a go.
Dickkyboy I think your figures for the new products are not correct. Feel free to correct mine.
It is entirely possible that management won't deliver on their business plans but below is their business plan for the new products.
As far as Nextstellis goes, yes it will still be in the red this year. Plan is for 350000 cycles FY 23 and the first 4 months they achieved $A96/cycle, so that's $Am 36 FY23 and expenses likely to be $US 35M (FY22 figures included set up costs) so that's $A50m plus COS of about $A6.5m, so contribution for Nexstellis likely to be -$A21.
I also have some figures on Dermatology which in my opinion is key to the turnaround of this company.
| New Products |
| 2HFY23 $Am |
|
|
|
|---|
| 1 | Net Revenue |
| $65.07 | Based on Last 9 months Therapeutics | 70c exchange |
|
|---|
| 2 | COS |
| $12.36 | 19% | As per Therapeutics |
|
|---|
| 3 | Therapeutics Royalties |
| $5.21 | 8% |
|
|
|---|
| 4 | Pop.Council Royalties |
| $3.54 | 10% | Annovera sales only |
|
|---|
| 5 | Extra Marketing |
| $14.29 | $US 10M | As disclosed
HF year only |
|
|---|
| 6 | Total Costs |
| $35.40 |
|
|
|
|---|
| 7 | Contribution |
| $29.68 |
|
|
|
|---|
| 8 | Additional Marketing |
| Covered by Nestellis as disclosed |
|
|
|
|---|
(20min delay)